Current Report Filing (8-k)
April 08 2019 - 12:35PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event
Reported): April 5, 2019
GW PHARMACEUTICALS
PLC
(EXACT NAME OF REGISTRANT AS SPECIFIED IN
ITS CHARTER)
England and Wales
(State or other jurisdiction of incorporation)
|
001-35892
(Commission File Number)
|
N/A
(I.R.S. Employer Identification No.)
|
Sovereign House, Vision Park Chivers
Way, Histon Cambridge, CB24 9BZ United Kingdom
(Address of Principal Executive Offices, including Zip Code)
Telephone: +44 1223 266 800
(Registrant’s Telephone Number, Including Area Code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether
the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging Growth Company
¨
If an
emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section13(a) of the Exchange Act
¨
Item 2.01. Completion of Acquisition or Disposition of Assets.
On April 5, 2019, GW Research Ltd., the principal research subsidiary
of GW Pharmaceuticals plc (the “Company”), satisfied the closing conditions contained in the previously announced priority
review voucher (PRV) Transfer Agreement with Biohaven Pharmaceutical Holding Ltd. The transaction closed on the same day and the
Company received the cash proceeds of $105 million.
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Dated: April 8, 2019
|
GW PHARMACEUTICALS PLC
|
|
|
|
|
|
By:
|
/s/ Douglas B. Snyder
|
|
|
|
Name: Douglas B. Snyder
|
|
|
Title: Chief Legal Officer
|